Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-25-001610
Filing Date
2025-08-07
Accepted
2025-08-07 16:06:42
Documents
69
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q cldx-20250630x10q.htm   iXBRL 10-Q 1415469
2 EX-31.1 cldx-20250630xex31d1.htm EX-31.1 12613
3 EX-31.2 cldx-20250630xex31d2.htm EX-31.2 12602
4 EX-32.1 cldx-20250630xex32d1.htm EX-32.1 9350
  Complete submission text file 0001410578-25-001610.txt   6519173

Data Files

Seq Description Document Type Size
5 EX-101.SCH cldx-20250630.xsd EX-101.SCH 36585
6 EX-101.CAL cldx-20250630_cal.xml EX-101.CAL 42284
7 EX-101.DEF cldx-20250630_def.xml EX-101.DEF 152986
8 EX-101.LAB cldx-20250630_lab.xml EX-101.LAB 353793
9 EX-101.PRE cldx-20250630_pre.xml EX-101.PRE 253438
72 EXTRACTED XBRL INSTANCE DOCUMENT cldx-20250630x10q_htm.xml XML 1310058
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Filer) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-15006 | Film No.: 251193941
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)